Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two Form Vanguard For First US Rivals to Banzel Suspension

Executive Summary

Two companies now hold final US approvals for generics of Eisai’s Banzel oral suspension. But patent-litigation settlements could delay the entry of Bionpharma and Hikma to market.

You may also be interested in...

Hikma Offers Update On Plans For Advair Rival

Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.

Hikma’s balance sheet is a bonus for chief Olafsson

As the US pricing situation continues to bite, industry veteran and newly-appointed Hikma chief executive officer Siggi Olafsson is confident the company’s superior balance sheet and diversified business operation, spread across three regions, will provide a competitive advantage. Dean Rudge reports.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts